Chimeric antigen receptor T-cell therapy - Immune Therapeutics/Super-T Cell Cancer Company

Drug Profile

Chimeric antigen receptor T-cell therapy - Immune Therapeutics/Super-T Cell Cancer Company

Alternative Names: Chimeric Super Antigen Receptor T cell (CAR-T) cocktail therapy; Super CAR-T Cocktail therapy

Latest Information Update: 30 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Immune Therapeutics; Super T Cell Cancer Company
  • Developer Immune Therapeutics
  • Class CAR-T cell therapies
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Cancer

Most Recent Events

  • 21 Apr 2016 Clinical trials in Cancer in China (Parenteral) before April 2016
  • 21 Apr 2016 Immune Therapeutics in-licenses Chinese Chimeric Super Antigen T cell (CAR-T) cocktail therapy from Super-T Cell Cancer Company
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top